Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs

Biomaterials

Volumn 34, Issue 12, 2013, Pages 3098-3109

  Joo, Kye Il ^a   Xiao, Liang ^a   Liu, Shuanglong ^b   Liu, Yarong ^a   Lee, Chi Lin ^a   Conti, Peter S ^b   Wong, Michael K ^c   Li, Zibo ^b   Wang, Pin ^a,d  

^a University of Southern California ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer therapy; Crosslinked multilamellar liposome; Doxorubicin; Intracellular trafficking; Nanomedicine; Positron emission tomography (PET)

Indexed keywords

ANTICANCER DRUG; CANCER THERAPEUTICS; CANCER THERAPY; CONTROLLED DELIVERY; CROSSLINKED; DOXORUBICIN; DRUG PACKAGING; DRUG RELEASE; DRUG RELEASE KINETICS; IN-VIVO EXPERIMENTS; INHERENT INSTABILITY; INTRACELLULAR TRAFFICKING; LIPID COMPOSITION; LIPOSOMAL FORMULATION; MULTILAMELLAR LIPOSOMES; NANOCARRIERS; THERAPEUTIC ACTIVITY; TUMOR GROWTH; UNILAMELLAR LIPOSOMES;

DISEASES; LIPOSOMES; MEDICAL NANOTECHNOLOGY; POSITRON EMISSION TOMOGRAPHY;

DRUG PRODUCTS;

CAVEOLIN; CHELATING AGENT; DOXORUBICIN; LIPOSOME; TETRAXETAN COPPER 64; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL VACUOLE; CONTROLLED STUDY; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; FEMALE; HELA CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED C57BL;

EID: 84873455346     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.039     Document Type: Article

References (52)

1. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
2. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
3. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
4. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
5. Cho K.J., Wang X., Nie S.M., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
6. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
7. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
8. Park J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002, 4:93-97.
9. Drummond D.C., Noble C.O., Hayes M.E., Park J.W., Kirpotin D.B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008, 97:4696-4740.
10. Haran G., Cohen R., Bar L., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993, 1151:201-215.
11. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001, 19:424-436.
12. O'Shaughnessy J.A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003, 4:318-328.
13. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001, 7:223-225.
14. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
15. Laginha K.M., Verwoert S., Charrois G.J.R., Allen T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005, 11:6944-6949.
16. Al-Jamal W.T., Al-Ahmady Z.S., Kostarelos K. Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia. Biomaterials 2012, 33:4608-4617.
17. van Lummel M., van Blitterswijk W.J., Vink S.R., Veldman R.J., van der Valk M.A., Schipper D., et al. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J 2011, 25:280-289.
18. Barenholz Y. Doxil - the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
19. Charrois G.J.R., Allen T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004, 1663:167-177.
20. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H.P., Huang B., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
21. Itaya K., Ui M. A new micromethod for the colorimetric determination of inorganic phosphate. Clin Chim Acta 1966, 14:361-366.
22. Cai H., Li Z., Huang C.W., Park R., Shahinian A.H., Conti P.S. An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl) benzoic acid, for 64Cu radiopharmaceuticals. Nucl Med Biol 2010, 37:57-65.
23. Dos Santos N., Allen C., Doppen A.M., Anantha M., Cox K.A.K., Gallagher R.C., et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 2007, 1768:1367-1377.
24. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-744.
25. Allen T.M., Mumbengegwi D.R., Charrois G.J.R. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005, 11:3567-3573.
26. Charrois G.J.R., Allen T.M. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 2003, 306:1058-1067.
27. Charrois G.J.R., Allen T.M. Rate of biodistribution of stealth liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 2003, 1609:102-108.
28. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
29. Dobson P.D., Kell D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat Rev Drug Discov 2008, 7:205-220.
30. Le Roy C., Wrana J.L. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005, 6:112-126.
31. Mayor S., Pagano R.E. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007, 8:603-612.
32. Pelkmans L., Helenius A. Endocytosis via caveolae. Traffic 2002, 3:311-320.
33. Neufeld E.B., Cooney A.M., Pitha J., Dawidowicz E.A., Dwyer N.K., Pentchev P.G., et al. Intracellular trafficking of cholesterol monitored with a cyclodextrin. J Biol Chem 1996, 271:21604-21613.
34. Rothberg K.G., Heuser J.E., Donzell W.C., Ying Y.S., Glenney J.R., Anderson R.G.W. Caveolin, a protein-component of caveolae membrane coats. Cell 1992, 68:673-682.
35. Wang L.H., Rothberg K.G., Anderson R.G.W. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993, 123:1107-1117.
36. Pelkmans L., Burli T., Zerial M., Helenius A. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell 2004, 118:767-780.
37. Parton R.G., Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007, 8:185-194.
38. Hayer A., Stoeber M., Ritz D., Engel S., Meyer H.H., Helenius A. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J Cell Biol 2010, 191:615-629.
39. Christoforidis S., McBride H.M., Burgoyne R.D., Zerial M. The Rab5 effector EEA1 is a core component of endosome docking. Nature 1999, 397:621-625.
40. Carlsson S.R., Roth J., Piller F., Fukuda M. Isolation and characterization of human lysosomal membrane-glycoproteins, h-lamp-1 and h-lamp-2-major sialoglycoproteins carrying polylactosaminoglycan. J Biol Chem 1988, 263:18911-18919.
41. Luzio J.P., Brake B., Banting G., Howell K.E., Braghetta P., Stanley K.K. Identification, sequencing and expression of an integral membrane-protein of the trans-golgi network (TGN38). Biochem J 1990, 270:97-102.
42. Li Z., Jin Q., Huang C., Dasa S., Chen L., Yap L.-P., et al. Trackable and targeted phage as positron emission tomography (PET) agent for cancer imaging. Theranostics 2011, 1:371-380.
43. Cai H., Fissekis J., Conti P.S. Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and 64Cu radiolabelling. Dalton Trans 2009, 5395-5400.
44. Held K., Sylvester F., Hopcia K., Biaglow J. Role of Fenton chemistry in thiol-induced toxicity and apoptosis. Radiat Res 1996, 145:542-553.
45. Huth U.S., Schubert R., Peschka-Suss R. Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J Control Release 2006, 110:490-504.
46. Pollock S., Antrobus R., Newton L., Kampa B., Rossa J., Latham S., et al. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J 2010, 24:1866-1878.
47. Pelkmans L., Kartenbeck J., Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001, 3:473-483.
48. Torgersen M.L., Skretting G., van Deurs B., Sandvig K. Internalization of cholera toxin by different endocytic mechanisms. J Cell Sci 2001, 114:3737-3747.
49. Smith J.L., Campos S.K., Wandinger-Ness A., Ozbun M.A. Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J Virol 2008, 82:9505-9512.
50. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003, 42:419-436.
51. Andresen T.L., Jensen S.S., Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 2005, 44:68-97.
52. Mouritsen O.G., Jorgensen K. A new look at lipid-membrane structure in relation to drug research. Pharm Res 1998, 15:1507-1519.